Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Thiazolidinediones or Thiazolidinediones and Metformin

This study has been completed.
Sponsor:
Collaborator:
Eli Lilly and Company
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00099320
First received: December 10, 2004
Last updated: June 6, 2014
Last verified: June 2014
  Purpose

This study is designed to compare the effects of twice-daily exenatide plus oral antidiabetic (OAD) agents and twice-daily placebo plus OAD with respect to glycemic control, as measured by hemoglobin A1c (HbA1c), in patients with type 2 diabetes who experience inadequate glycemic control with OAD alone.


Condition Intervention Phase
Type 2 Diabetes Mellitus
Drug: exenatide
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Thiazolidinediones or Thiazolidinediones and Metformin

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Change in HbA1c (glycosylated hemoglobin) from Baseline to Week 16, and if measured, any visits in between [ Time Frame: Baseline, Week 4, Week 8, Week 12, Week 16 ] [ Designated as safety issue: No ]
    Change in HbA1c from Baseline (Visit 3) to study termination at Week 16, and at all study visits in between

  • Change from Baseline to Week 16 in fasting serum glucose (FSG) and glucose [ Time Frame: Baseline, Week 16 ] [ Designated as safety issue: No ]
    Change from Baseline to Week 16 in FSG and glucose measured at different times throughout the day derived from 7-point self-monitored glucose (SMG) profile (glucose measurements before and 2 hours after the start of the morning, midday, and evening meals, and at bedtime)


Secondary Outcome Measures:
  • Percentage of subjects reaching the target HbA1c (<7%) [ Time Frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16 ] [ Designated as safety issue: No ]
    The percentage of subjects reaching the target HbA1c (<7%) will be summarized and compared by treatment

  • Change in body weight from Baseline to Week 16 [ Time Frame: Baseline, Week 16 ] [ Designated as safety issue: No ]
    Change in body weight (kg) from Baseline to Week 16

  • Change from Baseline to Week 16 in fasting serum glucose (FSG) and glucose [ Time Frame: Baseline, Week 16 ] [ Designated as safety issue: No ]
    Change from Baseline to Week 16 in FSG and glucose measured at different times throughout the day derived from 7-point self-monitored glucose (SMG) profile (glucose measurements before and 2 hours after the start of the morning, midday, and evening meals, and at bedtime)

  • Changes in beta cell function and insulin sensitivity between Baseline and Week 16 [ Time Frame: Baseline, Week 16 ] [ Designated as safety issue: No ]
    Changes in beta cell function and insulin sensitivity as assessed by homeostasis model assessment (HOMA) analyses and the proinsulin/insulin ratio Between Baseline and Week 16

  • Changes in lipids between Baseline and Week 16 [ Time Frame: Baseline, Week 16 ] [ Designated as safety issue: No ]
    Changes from Baseline to Week 16 in serum lipids (total cholesterol [TC], high-density lipoprotein cholesterol [HDL-C], fasting triglycerides, calculated low-density lipoprotein cholesterol [LDL-C]


Enrollment: 182
Study Start Date: May 2004
Study Completion Date: August 2005
Primary Completion Date: August 2005 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Exenatide
After a 2-week placebo lead-in period, exenatide will be given in an esclating dose along with the subject's current therapy regimen
Drug: exenatide
After a 2-week placebo lead-in period (twice daily, given subcutaneously) in addition to their current therapy regimen, subjects will administer 20 mcg of exenatide (2 units [5 μg] ), twice daily by subcutaneous injection, for the first 4 weeks of therapy, and then 40 μL of study drug (4 units [10 μg] of exenatide) twice daily by subcutaneous injection, for the remaining 12 weeks of therapy.
Other Names:
  • Byetta
  • AC2993
  • synthetic exendin-4
Placebo Comparator: Placebo
After a 2-week placebo lead-in period, subjects will be given placebo (in equivalent amounts to exenatide) in addition to their current therapy regimen.
Drug: Placebo
After a 2-week placebo lead-in period (twice daily, given subcutaneously) in addition to their current therapy regimen, subjects will administer placebo (in equivalent amounts to exenatide) for 16 weeks of therapy.

  Eligibility

Ages Eligible for Study:   21 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Treated with thiazolidinedione (TZD) alone or in combination with metformin. TZD dose stable for at least 120 days prior to screening, and those patients on metformin must have been on a stable dose for at least 30 days prior to screening.
  • HbA1c between 7.1% and 10.0%, inclusive.
  • Body mass index (BMI) between 25 kg/m^2 and 45 kg/m^2.

Exclusion Criteria:

  • Patient previously in a study using exenatide or GLP-1 analogs.
  • Treated with oral anti-diabetic medications other than TZD and metformin within 3 months of screening.
  • Treated with oral insulin within 3 months of screening.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00099320

  Hide Study Locations
Locations
United States, Alabama
Research Site
Birmingham, Alabama, United States
United States, California
Research Site
La Jolla, California, United States
Research Site
San Mateo, California, United States
Research Site
Santa Barbara, California, United States
Research Site
Spring Valley, California, United States
United States, Florida
Research Site
Hialeah, Florida, United States
Research Site
Jacksonville, Florida, United States
Research Site
Melbourne, Florida, United States
Research Site
West Palm Beach, Florida, United States
United States, Georgia
Research Site
Atlanta, Georgia, United States
United States, Hawaii
Research Site
Honolulu, Hawaii, United States
United States, Idaho
Research Site
Idaho Falls, Idaho, United States
United States, Illinois
Research Site
Chicago, Illinois, United States
United States, Louisiana
Research Site
Baton Rouge, Louisiana, United States
United States, Michigan
Research Site
Kalamazoo, Michigan, United States
Research Site
Troy, Michigan, United States
United States, Montana
Research Site
Butte, Montana, United States
United States, Nebraska
Research Site
McCook, Nebraska, United States
Research Site
North Platte, Nebraska, United States
Research Site
Omaha, Nebraska, United States
Research Site
Scottsbluff, Nebraska, United States
United States, New Jersey
Research Site
Princeton, New Jersey, United States
United States, New Mexico
Research Site
Albuquerque, New Mexico, United States
United States, New York
Research Site
Albany, New York, United States
Research Site
New York, New York, United States
Research Site
Rochester, New York, United States
United States, North Carolina
Research Site
Greenville, North Carolina, United States
United States, Ohio
Research Site
Cleveland, Ohio, United States
United States, South Carolina
Research Site
Greenville, South Carolina, United States
United States, Tennessee
Research Site
Chattanooga, Tennessee, United States
Research Site
Knoxville, Tennessee, United States
United States, Texas
Research Site
Dallas, Texas, United States
Research Site
Georgetown, Texas, United States
Research Site
San Antonio, Texas, United States
Research Site
The Colony, Texas, United States
United States, Washington
Research Site
Olympia, Washington, United States
Research Site
Renton, Washington, United States
Research Site
Tacoma, Washington, United States
United States, West Virginia
Research Site
Charleston, West Virginia, United States
Research Site
Huntington, West Virginia, United States
Canada, Alberta
Research Site
Calgary, Alberta, Canada
Canada, British Columbia
Research Site
Vancouver, British Columbia, Canada
Canada, Nova Scotia
Research Site
Dartmouth, Nova Scotia, Canada
Canada, Ontario
Research Site
London, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Canada, Quebec
Research Site
Montreal, Quebec, Canada
Spain
Research Site
Granada, Spain
Research Site
Sevilla, Spain
Research Site
Valencia, Spain
Research Site
Valladolid, Spain
Research Site
Zaragoza, Spain
Sponsors and Collaborators
AstraZeneca
Eli Lilly and Company
Investigators
Study Director: James Malone, MD Eli Lilly and Company
  More Information

No publications provided by AstraZeneca

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT00099320     History of Changes
Other Study ID Numbers: H8O-MC-GWAP
Study First Received: December 10, 2004
Last Updated: June 6, 2014
Health Authority: United States: Food and Drug Administration
Canada: Health Canada
Spain: Spanish Agency of Medicines

Keywords provided by AstraZeneca:
exenatide
exendin-4
diabetes
Amylin
Lilly

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Exenatide
2,4-thiazolidinedione
Metformin
Hypoglycemic Agents
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on July 26, 2014